A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: mRNA-1018 for H5 OnlyBiological: mRNA-1018 for H7N9Biological: mRNA-1018 for H5 Only-CGBiological: mRNA-1018 for H5N8Biological: mRNA-1018 for H7 Only
- Registration Number
- NCT05972174
- Lead Sponsor
- ModernaTX, Inc.
- Brief Summary
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1504
- Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and results of electrocardiogram testing.
- Body mass index of 18 kilograms (kg)/square meter (m^2) to 39 kg/m^2 (inclusive) at the Screening visit.
- For female participants of childbearing potential: negative pregnancy test, adequate contraception, and not currently breastfeeding.
Key
- Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
- History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
- Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
- Participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 180 days prior to Screening Visit (for corticosteroids ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
- Participant has received any vaccine authorized or approved by local health agency including mRNA vaccine ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention.
- Participant has participated in an interventional clinical study within 28 days prior to the Screening visit based on the medical history interview or plans to do so while participating in this study.
Other inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 1 mRNA-1018 for H5 Only Participants will receive mRNA-1018 for H5 only at dose level 1 by IM injection on Day 1 and Day 22. Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 3 mRNA-1018 for H7N9 Participants will receive mRNA-1018 for H7N9 at dose level 3 by IM injection on Day 1 and Day 22. Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 2 mRNA-1018 for H5 Only-CG Participants will receive mRNA-1018 for H5 Only-CG at dose level 2 by IM injection on Day 1 and Day 22. Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 2 mRNA-1018 for H5 Only Participants will receive mRNA-1018 for H5 only at dose level 2 by IM injection on Day 1 and Day 22. Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 3 mRNA-1018 for H5 Only Participants will receive mRNA-1018 for H5 only at dose level 3 by IM injection on Day 1 and Day 22. Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 3 mRNA-1018 for H5 Only-CG Participants will receive mRNA-1018 for H5 Only-CG at dose level 3 by IM injection on Day 1 and Day 22. Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 2 mRNA-1018 for H5N8 Participants will receive mRNA-1018 for H5N8 at dose level 2 by IM injection on Day 1 and Day 22. Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 2 mRNA-1018 for H7 Only Participants will receive mRNA-1018 for H7 only at dose level 2 by IM injection on Day 1 and Day 22. Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 1 mRNA-1018 for H5 Only-CG Participants will receive mRNA-1018 for H5 Only-CG at dose level 1 by IM injection on Day 1 and Day 22. Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 3 mRNA-1018 for H5N8 Participants will receive mRNA-1018 for H5N8 at dose level 3 by IM injection on Day 1 and Day 22. Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 3 mRNA-1018 for H7 Only Participants will receive mRNA-1018 for H7 only at dose level 3 by IM injection on Day 1 and Day 22. Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 1 mRNA-1018 for H5N8 Participants will receive mRNA-1018 for H5N8 at dose level 1 by intramuscular (IM) injection on Day 1 and Day 22. Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 1 mRNA-1018 for H7N9 Participants will receive mRNA-1018 for H7N9 at dose level 1 by IM injection on Day 1 and Day 22. Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 2 mRNA-1018 for H7N9 Participants will receive mRNA-1018 for H7N9 at dose level 2 by IM injection on Day 1 and Day 22. Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 1 mRNA-1018 for H7 Only Participants will receive mRNA-1018 for H7 only at dose level 1 by IM injection on Day 1 and Day 22.
- Primary Outcome Measures
Name Time Method Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) Up to Day 29 (7 days after each injection) Number of Participants with Medically-Attended AEs (MAAEs) Day 1 to Day 205 (EoS) Number of Participants with Serious Adverse Events (SAEs) Day 1 to Day 205 (EoS) Number of Participants with Unsolicited Adverse Events (AEs) Up to Day 43 (21 days after each injection) Number of Participants with AEs Leading to Discontinuation From Study Day 1 to Day 205 (end of study [EoS]) Number of Participants with Adverse Events of Special Interest (AESIs) Day 1 to Day 205 (EoS)
- Secondary Outcome Measures
Name Time Method Number of Participants With HAI Titer ≥ 1:40 at Days 22, 29, and 43 Days 22, 29, and 43 Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies From Baseline to Days 22, 29, and 43, as Measured by HAI Assay Baseline (Day 1), Days 22, 29, and 43 Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Days 22, 29, and 43, as Measured by Hemagglutination Inhibition (HAI) Assay Days 22, 29, and 43 Number of Participants With Seroconversion at Days 22, 29, and 43, as Measured by HAI Assay Baseline (Day 1) to Days 22, 29, and 43 Seroconversion is defined as a Day 22, 29, or 43 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay.
GMT of Anti-Neuraminidase (NA) Antibodies at Days 22, 29, and 43, as Measured by Neuraminidase Inhibition (NAI) Assay Days 22, 29, and 43 GMFR of Anti-NA Antibodies From Baseline to Days 22, 29, and 43, as Measured by NAI Assay Baseline (Day 1), Days 22, 29, and 43 Number of Participants with a Change in the Days 22, 29, and 43 NAI Titer of at Least 2-/3-/4-Fold Rise Baseline (Day 1) to Days 22, 29, and 43 Number of participants with a change in the Days 22, 29, or 43 NAI titer of at least 2-/3-/4-fold rise, defined as ≥2-/3-/4-fold of the lower level of quantitation (LLOQ) if the Day 1 titer is \<LLOQ; or ≥2-/3-/4-fold of the Day 1 titer if the Day 1 titer is ≥LLOQ.
Trial Locations
- Locations (23)
Royal Victoria Infirmary
🇬🇧Newcastle upon Tyne, England, United Kingdom
University Hospitals Birmingham
🇬🇧Birmingham, London, United Kingdom
Chelsea and Westminster Hospital
🇬🇧London, United Kingdom
Quadram Institute NNUH CRF
🇬🇧Norwich, Norfolk, United Kingdom
Velocity Clinical Research
🇬🇧North Finchley, United Kingdom
University Hospitals
🇬🇧Bristol, London, United Kingdom
Velocity Clinical Research Providence
🇺🇸East Greenwich, Rhode Island, United States
University College London Hospitals NHS Foundation Trust
🇬🇧London, United Kingdom
Lakeside Healthcare Research Unit
🇬🇧Corby, Northamptonshire, United Kingdom
Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
🇬🇧London, United Kingdom
Northern Care Alliance
🇬🇧Salford, London, United Kingdom
Royal Free Hospital
🇬🇧London, United Kingdom
Cardiff and Vale University
🇬🇧Cardiff, London, United Kingdom
North Wales Clinical Research Centre
🇬🇧Wrexham, London, United Kingdom
St Georges Vaccine Institute Cranmer Terrace
🇬🇧London, United Kingdom
Royal Cornwall Hospital
🇬🇧Truro, London, United Kingdom
Western Hospital Edinburgh
🇬🇧Edinburgh, United Kingdom
Johnson County Clin-Trials
🇺🇸Lenexa, Kansas, United States
J. Lewis Research, Inc/Jordan River Family Medicine
🇺🇸South Jordan, Utah, United States
Southampton General Hospital
🇬🇧Southampton, England, United Kingdom
Bradford Teaching Hospitals NHS Foundation Trust
🇬🇧Bradford, London, United Kingdom
CenExel RCA
🇺🇸Hollywood, Florida, United States
DM Clinical Research
🇺🇸Tomball, Texas, United States